Guardian Metal Resources Announces Pilot Mountain Pre - Feasibility Study Results

The article says tungsten has outperformed gold, silver and copper over the past year and that the U.S. has not mined tungsten since 2015, while China supplies about 80% of global tungsten and nearly 90% of processing. It notes a U.S. defense rule from Jan 1, 2027 banning tungsten routed through China. It highlights Blue Moon Metals (TSXV: MOON, NASDAQ: BMM) acquiring 33 tungsten and antimony projects near its Springer complex, with consideration including 2.8M shares, $5.0M cash, and a 1% NSR r

Tungsten APT prices have risen about 557% since China added tungsten products to export controls in Feb. 2025, pushing the European benchmark toward US$2,250/mt unit by March 2026, according to the article. GoldHaven (CSE: GOH) highlighted its 37,000-hectare Magno Project in BC, citing historical tungsten results up to 6,550 ppm and indium up to 334 ppm, and plans for 2026 drill testing. The release also notes Canada’s expanded 30% critical-minerals tax credit for tungsten and a U.S. DoD acquisi

Altimmune (ALT) reported Q2 results, highlighting progress in three liver disease trials. The company launched a global Phase 3 trial for MASH, reported positive Phase 2 data for alcohol use disorder, and completed enrollment for a Phase 2 trial in alcohol-associated liver disease. Altimmune has no approved products and reported a net loss of $22.8 million, with cash reserves of $519 million as of June 30.

NVIDIA's equity investments in AI companies totaled $99 billion, up from $7 billion a year ago. Key investments include OpenAI ($30B), Hugging Face ($12.9B), and Anthropic ($10B). The company's Q2 2027 revenue was $96.2B, up 106% YoY, with data center revenue at $89B, up 117%. NVIDIA is also involved in $500B in AI infrastructure financing. Investments aim to secure customers, create dependencies, and gain equity upside, but also expose NVIDIA to market risks and potential regulatory scrutiny.

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.